Medacta Group SA Delivers Robust First‑Half 2025 Performance

Medacta Group SA, the Swiss‑based health‑technology specialist listed on the SIX Swiss Exchange, announced a significant up‑turn in its first‑half results, underscoring the company’s resilient growth trajectory and reinforcing its market leadership in orthopedic and neurosurgical devices.

Revenue and EBITDA Growth

The company reported €344.1 million in revenue for H1 2025, representing a 19.8 % rise in constant currency (CC) and a 19.2 % increase in nominal terms. Adjusted EBITDA expanded by 27.5 % to €98.8 million, translating into a 29.6 % margin in CC, up 270 basis points year‑over‑year. This margin lift reflects disciplined cost management and a higher mix of high‑margin products, driven by the continued expansion of Medacta’s portfolio across the orthopaedic and neurosurgical segments.

Net Profit and Outlook

Net profit surged by 58 % year‑over‑year to €60.0 million, inclusive of one‑off gains. The robust earnings profile confirms the company’s capacity to convert revenue growth into shareholder value. CEO Francesco Siccardi highlighted the company’s “continued solid performance driven by a sustained above‑market growth in all business lines,” and emphasized Medacta’s position as a “unique driver of out‑of‑the‑box thinking innovations.”

Looking ahead, Medacta reaffirms its 2025 guidance and mid‑term outlook, signalling confidence in ongoing market demand and execution capability. The company’s strategic focus on innovation, coupled with its global distribution network, positions it favorably against competitors in the health‑care equipment sector.

Market Impact

At the close on 4 September 2025, Medacta’s share price traded at CHF 142.4, within a 52‑week range of CHF 103.6 to CHF 156.8. With a market capitalization of approximately CHF 2.99 billion and a price‑earnings ratio of 41.7, the stock remains an attractive proposition for investors seeking exposure to a high‑growth, technology‑driven segment of the health‑care industry.

Conclusion

Medacta Group SA’s first‑half 2025 results demonstrate a compelling blend of revenue acceleration, margin expansion, and earnings growth. The company’s strategic execution, supported by a robust product pipeline and global reach, positions it well to sustain momentum throughout the remainder of the fiscal year and beyond.